Area of research
Oncology · Cancer Research
Research interest
Research interests include Pancreatic and Hepatic Oncology Research, Colorectal Cancer Treatments and Studies, Cancer Treatment and Pharmacology, and Cancer Genomics and Diagnostics.
Gemcitabine, Cisplatin, and nab-Paclitaxel for the Treatment of Advanced Biliary Tract Cancers
Phase IB/II Randomized Study of FOLFIRINOX Plus Pegylated Recombinant Human Hyaluronidase Versus FOLFIRINOX Alone in Patients With Metastatic Pancreatic Adenocarcinoma: SWOG S1313
Phase 2 study of vismodegib, a hedgehog inhibitor, combined with gemcitabine and nab-paclitaxel in patients with untreated metastatic pancreatic adenocarcinoma
Response Rate Following Albumin-Bound Paclitaxel Plus Gemcitabine Plus Cisplatin Treatment Among Patients With Advanced Pancreatic Cancer
Development of MK-8353, an orally administered ERK1/2 inhibitor, in patients with advanced solid tumors
Phase II Study of BGJ398 in Patients With FGFR-Altered Advanced Cholangiocarcinoma
Phase I, Dose-Escalation, Two-Part Trial of the PARP Inhibitor Talazoparib in Patients with Advanced Germline <i>BRCA1/2</i> Mutations and Selected Sporadic Cancers
Phase 1 trials of PEGylated recombinant human hyaluronidase PH20 in patients with advanced solid tumours
Metastatic Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice Guideline
Structure-Guided Blockade of CSF1R Kinase in Tenosynovial Giant-Cell Tumor
Phase 2 study of <scp>MK</scp>‐2206, an allosteric inhibitor of <scp>AKT</scp>, as second‐line therapy for advanced gastric and gastroesophageal junction cancer: A SWOG cooperative group trial (<scp>S</scp>1005)
Dual blockade of epidermal growth factor receptor and insulin‐like growth factor receptor–1 signaling in metastatic pancreatic cancer: Phase Ib and randomized phase II trial of gemcitabine, erlotinib, and cixutumumab versus gemcitabine plus erlotinib (SWOG S0727)
Safety and antitumor activity of the PARP inhibitor BMN673 in a phase 1 trial recruiting metastatic small-cell lung cancer (SCLC) and germline BRCA-mutation carrier cancer patients.
STAG2 is a clinically relevant tumor suppressor in pancreatic ductal adenocarcinoma
Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
First-in-human trial of novel oral PARP inhibitor BMN 673 in patients with solid tumors.